AGTR1 and diabetes mellitus: A close association between RAS activation and diabetes has been confirmed by clinical trials showing the beneficial effects of ACE inhibitors (ACEis) and AT1R blockers (ARBs) on the incidence of DM, as well as on the reduction of cardiovascular complications in patients with DM [Heart Outcomes Prevention Evaluation (HOPE) and ONTARGET studies among others](33,34).